RxDoctor Payments Data

Amy Duncan, APRN

Family · Paducah, KYNPI 1568862951

Payments from drug & device makers

$5,682in general payments, 2019–2025

Across 331 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$586
  • Pfizer$498
  • Boehringer Ingelheim$408
  • Merck$381
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$367
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,682 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$82,289
Medicare patients
550
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban348$285,346
EntrestoSacubitril/Valsartan216$206,865
XareltoRivaroxaban106$127,782
Repatha SureclickEvolocumab171$121,811
BrilintaTicagrelor162$105,001
FarxigaDapagliflozin Propanediol107$84,413
MultaqDronedarone Hcl34$40,008
JardianceEmpagliflozin31$30,467
Repatha SyringeEvolocumab40$22,000
Praluent PenAlirocumab26$15,495
Ranolazine ErRanolazine139$14,300
Atorvastatin Calcium502$4,154
Metoprolol Succinate373$3,152
Isosorbide Mononitrate ErIsosorbide Mononitrate260$2,787
Prasugrel Hcl18$2,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$498$285,346348 claims
NovartisEntresto$1,396$206,865216 claims
AstraZenecaBrilinta, Farxiga$148$189,414269 claims
Johnson & JohnsonXarelto$159$127,782106 claims
Sanofi-aventis U.S. LLCMultaq$151$40,00834 claims
Boehringer IngelheimJardiance$408$30,46731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →